Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rank in Stocks #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Share Price
$64.97
Last synced: 2024-05-20
Market Cap
$1.97B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alpine Immune Sciences, Inc. (ALPN)

Category

EPS for Alpine Immune Sciences, Inc. (ALPN)
EPS as of March 2024 TTM: $-0.69
According to Alpine Immune Sciences, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-0.69. At the end of 2022 the company had a EPS of $-1.73 a decrease compared to its 2021 EPS that were of $-1.98.
EPS history for Alpine Immune Sciences, Inc. from 2012 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.69 7.81%
2023 $-0.64 -63.01%
2022 $-1.73 -12.63%
2021 $-1.98 47.76%
2020 $-1.34 -42.24%
2019 $-2.32 -11.79%
2018 $-2.63 119.17%
2017 $-1.20 -85.22%
2016 $-8.12 -16.63%
2015 $-9.74 47.80%
2014 $-6.59 -7.18%
2013 $-7.10 69.05%
2012 $-4.20 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -2,610.14%
US
$27.74 -4,120.29%
NL
$-5.29 666.67%
AU
$-7.98 1,056.52%
US
- -
CH